Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088522 · Präparat HOS-083663
Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive
medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole,
amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also
increase the risk of adverse reactions to zidovudine. If concomitant therapy with Combivir and any of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flucytosine (HOS-088525) vinblastine (HOS-086220) vincristine (HOS-086219) amphotericin (HOS-088524) pentamidine (HOS-085605) ganciclovir (HOS-085194) doxorubicin (HOS-084538) pyrimethamine (HOS-088523) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 630f15f3aa0679e134693606ce8bb2db3318cda621afe444c3d4ca4706aeffef · Zeichen 11429–11818 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089155 · Präparat HOS-083799
6
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 51310a74f30b964c7791524bf84074d7bc087b7392957520e24cde77e6580a84 · Zeichen 1715–2596 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 22–23
HOS-089199 · Präparat HOS-083799
22
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 3841af3357a6b556ffbe1ba585eac1e7bf20f0fc3570e5e588213cc0c4b3a13b · Zeichen 1717–2599 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 39–40
HOS-089235 · Präparat HOS-083799
39
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 9e66e50143ddafe6061884c102f65413737d52f3205579188f647249fcbe8333 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 56–57
HOS-089271 · Präparat HOS-083799
56
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 83195e0cd4d511eab05753997ff2bbd7c960dbb026602da219877011f99a7496 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 73–74
HOS-089307 · Präparat HOS-083799
73
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 937c091f055b54da7788615b0a8f796eec0d3e70caa79330356844a077ae478c · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089343 · Präparat HOS-083831
6
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 51310a74f30b964c7791524bf84074d7bc087b7392957520e24cde77e6580a84 · Zeichen 1715–2596 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 22–23
HOS-089377 · Präparat HOS-083831
22
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 3841af3357a6b556ffbe1ba585eac1e7bf20f0fc3570e5e588213cc0c4b3a13b · Zeichen 1717–2599 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 38–39
HOS-089412 · Präparat HOS-083831
38
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 23798f26c1d10735ac1103845757c251001803747d2fddf0cb05a19068a26188 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 55–56
HOS-089447 · Präparat HOS-083831
55
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage a26fad67a2ec8cdcb1ecacd438a628b3c48bc16decbc4fe714b306da0e88a2b6 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 72–73
HOS-089482 · Präparat HOS-083831
72
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage c2b7f360d8b561f093a743dca5f3f4c2e65c52ad578491d1b450764778643626 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-108573 · Präparat HOS-093047
Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive
medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole,
amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also
increase the risk of adverse reactions to zidovudine (see section 4.8). If concomitant therapy with
Trizivir and any of these medicinal products is necessary then extra care should be taken in monitoring
renal function and haematological parameters and, if required, the dosage of one or more agents
should be reduced.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flucytosine (HOS-088525) vinblastine (HOS-086220) vincristine (HOS-086219) amphotericin (HOS-088524) pentamidine (HOS-085605) ganciclovir (HOS-085194) doxorubicin (HOS-084538) pyrimethamine (HOS-088523) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage fadf52ee0ecc448cf34162a118a4ee0bbbc7fa1f124c0cc7fa32c024f4ee7a11 · Zeichen 16340–16946 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-110352 · Präparat HOS-093371
Medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics,
laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid and
derivatives)
If these substances are to be prescribed with the HCTZ-telmisartan combination, monitoring of
potassium plasma levels is advised. These medicinal products may potentiate the effect of HCTZ on
serum potassium (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): penicillin G sodium (HOS-089157) amphotericin (HOS-088524) salicylic acid (HOS-088803) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 351acce8662fb5095fc81eec209fbb6adc8f78db89de853d6549affea80dec21 · Zeichen 497–940 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 80 mg/25 mg tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-110431 · Präparat HOS-093371
Medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics,
laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid and
derivatives)
If these substances are to be prescribed with the HCTZ-telmisartan combination, monitoring of
potassium plasma levels is advised. These medicinal products may potentiate the effect of HCTZ on
serum potassium (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): penicillin G sodium (HOS-089157) amphotericin (HOS-088524) salicylic acid (HOS-088803) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 351acce8662fb5095fc81eec209fbb6adc8f78db89de853d6549affea80dec21 · Zeichen 497–940 im Abschnitt
Wechselwirkungen · Mycamine
Mycamine 50 mg powder for concentrate for solution for infusion Mycamine 100 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-117345 · Präparat HOS-094585
Drug interaction studies in healthy human subjects were conducted to evaluate the potential for
interaction between micafungin and mycophenolate mofetil, ciclosporin, tacrolimus, prednisolone,
sirolimus, nifedipine, fluconazole, ritonavir, rifampicin, itraconazole, voriconazole and amphotericin
B. In these studies, no evidence of altered pharmacokinetics of micafungin was observed. No
micafungin dose adjustments are necessary when these medicines are administered concomitantly.
Exposure (AUC) of itraconazole, sirolimus and nifedipine was slightly increased in the presence of
micafungin (22%, 21% and 18% respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) nifedipine (HOS-086289) amphotericin (HOS-088524) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) tacrolimus (HOS-085202) sirolimus (HOS-085172) ritonavir (HOS-084521) mycophenolate mofetil (HOS-085154)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T14:40:00Z · SHA-256 b10a8e41df9b387a8b080f2a96c5684a6a8901efa78aaf4c99c300096afa4cf9 · Passage cbe82a5c8fc5ae28a4114fd1888efec3a0d481da438e2fa59ffb5442277ef92b · Zeichen 105–730 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-117971 · Präparat HOS-094733
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage d42a28efc9f65817ce0a5b7ff2f2c1e0ceca7ebe8d0f2de72b385403ecd5a3d0 · Zeichen 1805–2682 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-118014 · Präparat HOS-094733
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage d42a28efc9f65817ce0a5b7ff2f2c1e0ceca7ebe8d0f2de72b385403ecd5a3d0 · Zeichen 1805–2682 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 41
HOS-118049 · Präparat HOS-094733
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage d42a28efc9f65817ce0a5b7ff2f2c1e0ceca7ebe8d0f2de72b385403ecd5a3d0 · Zeichen 1803–2680 im Abschnitt
Wechselwirkungen · Exforge HCT
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-121626 · Präparat HOS-095405
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Exforge HCT and NSAIDs may lead to worsening
cyclooxygenase-2 of renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) sulfinpyrazone (HOS-089177) sodium (HOS-109681) cisapride (HOS-085610) allopurinol (HOS-089178) diazoxide (HOS-088588) colestipol (HOS-089168) dantrolene (HOS-109261) atropine (HOS-089182) glucose (HOS-088412) amphotericin (HOS-088524) salicylic acid (HOS-088803) calcium (HOS-085615) lead (HOS-085592) amantadine (HOS-086615) biperiden (HOS-085953) probenecid (HOS-085208) uric acid (HOS-089176) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) guanethidine (HOS-088596) ritonavir (HOS-084521) potassium (HOS-086929) methyldopa (HOS-086564) penicillin G (HOS-121627) tubocurarine (HOS-089174) carbenoxolone (HOS-089156) iodine (HOS-087479) metformin (HOS-091032) methotrexate (HOS-087522) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T15:33:00Z · SHA-256 2096581c7b0afb2c48317340c55eeef559ee192a2bef927e9adeba55285d5694 · Passage 61bbc187393dbf47a0e8f64a7f5fde78d30721577fc88477dbb1075c82d35601 · Zeichen 4434–13491 im Abschnitt
Wechselwirkungen · Irbesartan/Hydrochlorothiazide Teva
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-211942 · Präparat HOS-154792
6
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based on the
experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use
of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other
medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in
serum potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T17:46:00Z · SHA-256 d153807aa78b933b85a74033d8ce9ad79fcd03f761c66d536fff8befc9ae2c26 · Passage cdc64f48a77dfbdb33ca88e48a310cdbb7fa9f1a2435cbb431d2e2d5e72de260 · Zeichen 1331–2211 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.